MedPath

Effect of Buspirone added to Typical Antipsychotics on Positive and Negative symptoms in schizophrenia

Phase 3
Conditions
Schizophrenia.
Schizophrenia
Registration Number
IRCT201106026691N1
Lead Sponsor
Mazandaran University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
50
Inclusion Criteria

Age between 18-65; Diagnosis of Schizophrenia based on DSMIV-TR; Chronic Schizophrenia(over 2 years); Ongoing treatment with Typical Antipsychotics.

Exclusion criteria:Allergic to Buspirone; Any chronic medical problem; Substance dependency; Any other Psychiatric Disorder in Axis I or II; Pregnancy or Breast feeding.

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Severity of schizophrenia. Timepoint: Baseline and weeks 2-4-6 after begining of treatment. Method of measurement: Positive and Negative Syndrome Scale(PANSS).
Secondary Outcome Measures
NameTimeMethod
Headache. Timepoint: Baseline and weeks 2,4,6 after begining of treatment. Method of measurement: Check list of adverse effects.;Nausea. Timepoint: Baseline and weeks 2-4-6 after begining of treatment. Method of measurement: Checklist of adverse effects.;Palpitation. Timepoint: Baseline and weeks 2-4-6 after begining of treatment. Method of measurement: Checklist of adverse effects.
© Copyright 2025. All Rights Reserved by MedPath